[{"id":"73e8506b-a82d-41df-b4ff-414021e9babc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03042221","created_at":"2021-01-18T14:58:44.313Z","updated_at":"2025-02-25T16:36:51.399Z","phase":"","brief_title":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","source_id_and_acronym":"NCT03042221","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRAF • ALK • ROS1 • CD8 • CDH1 • CD14 • VIM • MRC1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • ROS1 fusion","tags":["BRAF • ALK • ROS1 • CD8 • CDH1 • CD14 • VIM • MRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • ROS1 fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/10/2016","start_date":" 05/10/2016","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"2617ca5f-47d4-4a37-a652-3e4d4a06848f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03347838","created_at":"2023-11-29T17:14:43.874Z","updated_at":"2025-02-25T14:37:43.448Z","phase":"Phase 2","brief_title":"Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers","source_id_and_acronym":"NCT03347838","lead_sponsor":"University of Colorado, Denver","biomarkers":" PD-L1 • PD-1 • CD4 • CD68 • HLA-DRA • MRC1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1 • CD4 • CD68 • HLA-DRA • MRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-09-25"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"d248a372-e196-4938-a786-16c5881ac2c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02201420","created_at":"2021-04-20T07:52:25.888Z","updated_at":"2024-07-02T16:37:28.845Z","phase":"Phase 2","brief_title":"Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT","source_id_and_acronym":"NCT02201420","lead_sponsor":"Navidea Biopharmaceuticals","biomarkers":" MRC1","pipe":" | ","alterations":" MRC1 expression","tags":["MRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MRC1 expression"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2016-09-27"}]